Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of PRO-145 Emulsion for Post-Phacoemulsification Inflammation and Pain
NCT03693989Phase 3Completed
- Sponsor
- Laboratorios Sophia
- Start
- Oct 2018
- Primary completion
- Aug 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of difluprednate in post-operative inflammation and postoperative pain (2 arms), sponsored by Laboratorios Sophia. Primary endpoints: Visual Ability (VA) at 28 days and Adverse Events at 28 days. Started Oct 2018; status: completed.
02
Drugs
difluprednate
03
Conditions
post-operative inflammationpostoperative pain
Beyond the preview
Go deeper on NCT03693989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03693989.